Sunshine Biopharma Inc logo

Sunshine Biopharma Inc(SBFM)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$2.7
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SBFM

11/13/2026: SBFM (1-star) is currently NOT-A-BUY. Pass it for now.

Sunshine Biopharma is a hybrid biotech and consumer health company that balances speculative oncology drug development with a revenue-generating nutritional supplement business. Its primary strength lies in its diverse model, which aims to provide some operating stability while the company pursues high-potential cancer therapies like Adva-27a. However, the company faces significant risks, including historical net losses, dependence on continued capital raises, and intense competition from much larger pharmaceutical peers. This stock is best suited for high-risk investors interested in the biotech sector. Key developments to monitor include clinical trial outcomes, supplement revenue growth, and the company's ability to manage its cash burn rate without excessive dilution.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitThe company is in an early stage of drug development with high binary risk.
Momentum investorWeak fitMomentum is inconsistent and highly dependent on speculative biotech news cycles.
Value investorWeak fitThe company lacks established earnings or assets to justify a value-based investment.
Dividend investorWeak fitThere is no history of dividends and cash flow is prioritized for R&D.
Low-risk investorWeak fitThe company's reliance on clinical success makes it inherently high-risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighSpeculative biotech stocks often experience extreme price swings based on news flow.
Valuation riskHighValuation is difficult due to the lack of consistent profitability.
Competition risk (pharmaceutical competition)HighMajor pharmaceutical firms possess significantly more capital for R&D and marketing.
Business qualityMediumThe company has a diversified revenue model but limited scale.
Dividend incomeLow / noneCapital is retained strictly for business operations and research.
Execution riskHighSuccess depends entirely on the clinical development of complex oncology assets.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 2.22M USD
Price to earnings Ratio -
1Y Target Price 1120
Price to earnings Ratio -
1Y Target Price 1120
Volume (30-day avg) 615.3K shares
Beta 1.52
52 Weeks Range 2.53 - 464.00
Updated Date 11/14/2026
52 Weeks Range 2.53 - 464.00
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -189

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
66.7%
Active BUY / eligible
8 / 12
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -39.33%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SBFM receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
SBFM has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and moderate ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-16.4%), weak cash generation (FCF margin -15.2%), moderate revenue growth (+4.1%).

Financial Health Rating

★★★★★
SBFM's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 67.9%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is SBFM's strongest growth driver at +62.9% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (+4.1%, moderate) and earnings growth (-16.4%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 7.5% (soft) and 74.8% of outstanding shares are publicly tradable (solid). Insider ownership of 5.68% supports management-shareholder alignment.

Top 5 Institutional Investors

Jane Street Group LLC 0.35%
Morgan Stanley - Brokerage Accounts 0.01%
SBI Securities Co Ltd 0.00%
NATIONAL BANK OF CANADA /FI/ 0.00%
Advisor Group Holdings, Inc. 0.00%

Unit Economics (Per $1K Revenue)

★★★★★
SBFM generates approximately $328 of gross profit, $-123 of operating income, and $-152 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.36% (Tax Credit)

Quantitative Style Profile

★★★★★
SBFM has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Oncology TherapeuticsResearch and development of proprietary anti-cancer compounds.This is a high-risk, high-reward segment that does not currently provide regular revenue.
Nutritional SupplementsDirect-to-consumer sales of the Essential Nutrients brand.This segment provides the company's primary recurring revenue stream.

Valuation

Trailing PE -
Forward PE -
Enterprise Value -10.90M
Price to Sales(TTM) 0.06
Enterprise Value -10.90M
Price to Sales(TTM) 0.06
Enterprise Value to Revenue 0.02
Enterprise Value to EBITDA -7.73
Shares Outstanding 823.77K
Shares Floating 616.10K
Shares Outstanding 823.77K
Shares Floating 616.10K
Percent Insiders 5.68
Percent Institutions 7.55

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.